Baxter Healthcare Corporation

Baxter Healthcare Corporation
Share

Baxter is the world’s leading manufacturer of commercially prepared IV solutions as well as frozen and ready-to-use premixed drugs in flexible IV containers. Baxter’s portfolio of IV solutions and premixed drugs is the broadest in the industry. IV infusion pumps and administration sets control the delivery of IV fluids and drugs to patients.

Collaboration builds upon Baxter’s pending acquisition of Claris and its ScinoPharm collaboration and advances Baxter’s strategy of becoming a leader in generic injectables DEERFIELD, Ill., June 14, 2017 – Baxter International Inc. (NYSE: BAX), a global medical products company, today announced an agreement with Dorizoe Lifesciences Limited...

Only available premixed clindamycin injection in a saline presentation Provides additional access to commonly prescribed antibiotic in three standard doses Premixed presentation can help enhance patient safety and pharmacy efficiency DEERFIELD, Ill., June 7, 2017 – Baxter International Inc. (NYSE: BAX), a global leader in sterile medication...

Physicians using SHARESOURCE remote patient management – a telehealth platform – have more accurate and timely visibility to their patients’ home therapy adherence Remote patient management allows for earlier intervention in response to PD patient clinical issues
Nurses managing patients via remote patient management reported a 35 percent...

Five-year agreement brings together clinical and development expertise of two long-time healthcare leaders First project will focus on unmet needs in kidney disease treatment DEERFIELD, Ill. and JACKSONVILLE, Fla., MAY 31, 2017 – Baxter International Inc. (NYSE:BAX), a global medical products company, and Mayo Clinic today announced a new research...

Baxter presents results of seven studies at ISPOR 2017, one of the largest health economics and outcomes research (HEOR) conferences Studies analyzed critical areas of care for hospitals and health systems, including kidney disease, hospital malnutrition, medication delivery and surgery BOSTON, MAY 23, 2017 – Baxter International Inc. (NYSE: BAX),...

Innovative home dialysis solution generation system designed to enhance patients’ therapy experience New system may reduce barriers and offer more patients access to home therapy DEERFIELD, Ill., May 3, 2017 — Baxter International Inc. (NYSE: BAX), a global innovator in renal care, received guidance from the U.S. Food and Drug Administration (FDA)...

Guide covers comprehensive drug library development and integration with an electronic health record (EHR) Provides structure for drug library development that considers the entire medication pathway, from preparation to delivery DEERFIELD, Ill., April 20, 2017 – Baxter International Inc. (NYSE: BAX), a leader in innovative technology for...

New design for preparation of FLOSEAL enhances patient safety and accelerates preparation process with fewer components and steps TISSEEL Snap Lock Applicator provides greater maneuverability and more secure attachment during surgery
Hands-on demonstrations of both products available to attendees this week at AORN conference
BOSTON, APRIL 3,...

When hospitalized patients are malnourished due to not receiving adequate calories, protein and other nutrients needed for tissue maintenance and repair, there can be significant human and healthcare costs. In the U.S., malnourished inpatients: Have up to a five times greater likelihood of mortality and are two times more likely to have an...

Baxter Supports Launch of ISMP International Fellowship Program HORSHAM, Pa., and DEERFIELD, Ill., March 15, 2017 – The Institute for Safe Medication Practices (ISMP), with the support of Baxter International, is launching a two-year International Safe Medication Management Fellowship program. The goal of the program is to elevate awareness and to...